Cited by 320Virus-based gene therapy researchNeurogenetic and Muscular Disorders ResearchRNA Interference and Gene Delivery

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Death after High-Dose rAAV9 Gene Therapy in a Patient with Duchenne’s Muscular Dystrophy

Open access

Lek, Angela, Wong, Brenda, Keeler, Allison, Blackwood, Meghan, Ma, Kaiyue, Huang, Shushu, Sylvia, Katelyn, Batista, A. Rita, Artinian, Rebecca, Kokoski, Danielle, Parajuli, Shestruma, Putra, Juan, Carreon, C. Katte, Lidov, Hart, Woodman, Keryn, Pajusalu, Sander, Spinazzola, Janelle M., Gallagher, Thomas, LaRovere, Joan, Balderson, Diane, Black, Lauren, Sutton, Keith, Horgan, Richard, Lek, Monkol, Flotte, Terence·2023·New England Journal of Medicine

DOI 10.1056/nejmoa2307798PMC PMC11288170

Open this paper in CoChat — free account Open PDF

Abstract

We treated a 27-year-old patient with Duchenne’s muscular dystrophy (DMD) with recombinant adeno-associated virus (rAAV) serotype 9 containing dSaCas9 (i.e., “dead” Staphylococcus aureus Cas9, in which the Cas9 nuclease activity has been inactivated) fused to VP64; this transgene was designed to up-regulate cortical dystrophin as a custom CRISPR–transactivator therapy. The dose of rAAV used was 1×1014 vector genomes per kilogram of body weight. Mild cardiac dysfunction and pericardial effusion developed, followed by acute respiratory distress syndrome (ARDS) and cardiac arrest 6 days after transgene treatment; the patient died 2 days later. A postmortem examination showed severe diffuse alveolar damage. Expression of transgene in the liver was minimal, and there was no evidence of AAV serotype 9 antibodies or effector T-cell reactivity in the organs. These findings indicate that an innate immune reaction caused ARDS in a patient with advanced DMD treated with high-dose rAAV gene therapy. (Funded by Cure Rare Disease.)

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa2307798

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression
Qi, L. S., Larson, M. H., Gilbert, L. A., Doudna, J. A., Weissman, J. S., Arkin, A. P., & Lim, W. A. (2013) · Cell · doi:10.1016/j.cell.2013.02.022 · Cited by 5,016
CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering
Mali, P., Aach, J., Stranges, P. B., Esvelt, K. M., Moosburner, M., Kosuri, S., Yang, L., & Church, G. M. (2013) · Nature Biotechnology · doi:10.1038/nbt.2675 · Cited by 1,752
Analysis of AAV Serotypes 1–9 Mediated Gene Expression and Tropism in Mice After Systemic Injection
Zincarelli, C., Soltys, S., Rengo, G., & Rabinowitz, J. E. (2008) · Molecular Therapy · doi:10.1038/mt.2008.76 · Cited by 1,490
Duchenne muscular dystrophy
Duan, D., Goemans, N., Takeda, S., Mercuri, E. M., & Aartsma-Rus, A. M. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00248-3 · Cited by 1,345
Engineering adeno-associated virus vectors for gene therapy
Li, C., & Samulski, R. J. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-019-0205-4 · Cited by 1,175
Effect of genome size on AAV vector packaging
Wu, Z., Yang, H., & Colosi, P. (2010) · Molecular Therapy · doi:10.1038/mt.2009.255 · Cited by 1,029
The Dystrophin Glycoprotein Complex
Lapidos, K. A., Kakkar, R. K., & McNally, E. M. (2004) · Circulation Research · doi:10.1161/01.res.0000126574.61061.25 · Cited by 525
The Dystrophin Complex: Structure, Function, and Implications for Therapy
Gao, Q. Q., & McNally, E. M. (2015) · Comprehensive physiology · doi:10.1002/cphy.c140048 · Cited by 521
Systemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy
Duan, D. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.07.011 · Cited by 489

Flagged first, then by citations

Show all 26 references

Sorted by citations

Items 101–200 of 320

CRISPR-Based Transcriptional Regulation: Technologies, Applications, and Future Directions
Srinivasa, M. A., & Escobar, M. (2025) · DNA · doi:10.3390/dna5040057 · Cited by 11
Emerging trends in gene and cell therapy: CRISPR in DNA editing and beyond
Ji, R., Chen, Q., & Zhang, Y. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102459 · Cited by 14
Structural Changes Likely Cause Chemical Differences between Empty and Full AAV Capsids
Heldt, C. L., Skinner, M. A., & Anand, G. S. (2024) · Biomedicines · doi:10.3390/biomedicines12092128 · Cited by 12
Lung endothelial transduction in a patient that succumbed to acute respiratory distress syndrome following high-dose rAAV9 gene therapy
Hordeaux, J., Lamontagne, J., Bandyopadhyay, S., Bell, P. L., Wilson, J. M., & Flotte, T. R. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.05.017 · Cited by 10
Self-citation
AAV2.7m8 transduction of stage 2 human retinal organoids induces highly variable responses in innate and inflammatory gene expression and cytokine secretion
Sauter, M. M., Noel, H. R., Sinha, D., Nelson, E. C., Xiong, M. N., Gamm, D. M., & Brandt, C. R. (2025) · Experimental Eye Research · doi:10.1016/j.exer.2025.110478 · Cited by 10
Improving the safety of systemic viral gene therapy
McNally, E. M. (2024) · Journal of Clinical Investigation · doi:10.1172/jci177078 · Cited by 10
Next-generation strategies to improve safety and efficacy of adeno-associated virus-based gene therapy for hemophilia: lessons from clinical trials in other gene therapies
Minno, G. D., Miesbach, W., Castaman, G., & Peyvandi, F. (2024) · Haematologica · doi:10.3324/haematol.2023.284622 · Cited by 13
Generation of allogeneic and xenogeneic functional muscle stem cells for intramuscular transplantation
Lenardič, A., Domenig, S. A., Zvick, J., Bundschuh, N., Tarnowska-Sengül, M., Furrer, R., Noé, F., Trautmann, C. L., Ghosh, A., Bacchin, G., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci166998 · Cited by 9
Essential role of pre-existing humoral immunity in TLR9-mediated type I IFN response to recombinant AAV vectors in human whole blood
Alakhras, N. S., Moreland, C. A., Wong, L. C., Raut, P., Kamalakaran, S., Wen, Y., Siegel, R. W., & Malherbe, L. P. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1354055 · Cited by 10
Meeting Report: 2023 Muscular Dystrophy Association Summit on ‘Safety and Challenges in Gene Therapy of Neuromuscular Diseases’
Lek, A., Atas, E., Lin, B. L., Hesterlee, S. E., Abbott, J. K., Byrne, B. J., & Bönnemann, C. G. (2024) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-240002 · Cited by 9
Self-citation
Gene therapy for cardiac arrhythmias
Bains, S., Giudicessi, J. R., Odening, K. E., & Ackerman, M. (2025) · Nature Reviews Cardiology · doi:10.1038/s41569-025-01168-5 · Cited by 10
The future of gene therapy: Safer vectors, sharper focus
Chamberlain, J. S., Davidson, B. L., George, L. A., Byrne, B. J., & Barrett, D. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.08.029 · Cited by 9
Human umbilical cord mesenchymal stem cell-based gene therapy for hemophilia B using scAAV-DJ/8-LP1-hFIXco transduction
Bu, Z., Lou, J., Xu, W., Zhang, L., & Tang, Y. (2024) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-03824-y · Cited by 10
Targeted Gene Insertion: The Cutting Edge of CRISPR Drug Development with Hemophilia as a Highlight
Zhang, Z., Zhang, S., Wong, H. T., Li, D., & Feng, B. (2024) · BioDrugs · doi:10.1007/s40259-024-00654-5 · Cited by 9
Liver gene transfer for metabolite detoxification in inherited metabolic diseases
D’Alessio, A. M., Boffa, I., Stefano, L. D., Soria, L. R., & Brunetti‐Pierri, N. (2024) · FEBS Letters · doi:10.1002/1873-3468.14957 · Cited by 8
Dominantly inherited muscle disorders: understanding their complexity and exploring therapeutic approaches
Findlay, A. R. (2024) · Disease Models & Mechanisms · doi:10.1242/dmm.050720 · Cited by 9
From roadmap to a sustainable end-to-end individualized therapy pathway
Jonker, A., Tataru, E., Dimmock, D., Bateman-House, A., Graessner, H., Baynam, G., Augustine, E., Jaffe, A., Pasmooij, A. M., Iliach, O., et al. (2025) · Therapeutic Advances in Rare Disease · doi:10.1177/26330040251339204 · Cited by 9
Self-citation
CRISPR/Cas bioimaging: From whole body biodistribution to single-cell dynamics
Kolesova, E. P., Pulone, S., Kostyushev, D. S., & Tasciotti, E. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115619 · Cited by 9
Gene Editing Therapy in Cardiovascular Disease: 2026 ACC Scientific Statement
Ambardekar, A. V., Bhatt, A., Hoekstra, M., Kelly, M., Musunuru, K., & Natarajan, P. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.02.5092 · Cited by 10
Is Duchenne gene therapy a suitable treatment despite its immunogenic class effect?
Tang, A., & Yokota, T. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2447072 · Cited by 8
Endovascular transplantation of mRNA-enhanced mesenchymal stromal cells results in superior therapeutic protein expression in swine heart
Al‐Saadi, J., Waldén, M., Sandell, M., Sohlmér, J., Grankvist, R., Friberger, I., Andersson, A., Carlsten, M., Chien, K. R., Lundberg, J., et al. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101225 · Cited by 7
Systemic Treatment of Body‐Wide Duchenne Muscular Dystrophy Symptoms
Konieczny, P. (2024) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3363 · Cited by 7
Adeno-Associated Virus Vectors—a Target of Cellular and Humoral Immunity—are Expanding Their Reach Toward Hematopoietic Stem Cell Modification and Immunotherapies
Araujo, A. E., Bentler, M., Garmendia, X. P., Kaleem, A., Fabian, C., Morgan, M. A., Hacker, U. T., & Büning, H. (2024) · Human Gene Therapy · doi:10.1089/hum.2024.114 · Cited by 7
Investigation of dose-exposure-response relationship for adeno-associated virus–mediated delivery of antibody genes
Rajwade, A., Liu, S., Kumar, M., Ghobrial, A., Hahn, S., & Shah, D. K. (2025) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2025.103601 · Cited by 7
Improving the therapeutic efficacy of gene therapy for duchenne muscular dystrophy (DMD) by evaluating and managing inflammation
Raghavan, K., Ikewaki, N., Preethy, S., & Abraham, S. J. (2025) · Frontiers in Genetics · doi:10.3389/fgene.2025.1569289 · Cited by 7
Non-clinical safety considerations on genome editing using the CRISPR/Cas system
Toofan, P., Singh, M., Brööks, A. G., & McLuckie, K. (2025) · Genes & Diseases · doi:10.1016/j.gendis.2025.101785 · Cited by 6
A multifunctional theranostic ultrasound platform for remote magnetogenetics and expanded blood-brain barrier opening
Batts, A. J., Tsitsos, F. N., Ingabire, J., Duret, G., Gorman, S. L., Tsakri, D., Noel, R. L., Ji, R., Kwon, N., Pham, Q.-K., et al. (2025) · Brain stimulation · doi:10.1016/j.brs.2025.10.006 · Cited by 8
Virus-like particles based on plant viruses and bacteriophages: emerging strategies for the delivery of nucleic acid therapeutics
Kim, D., Duoto, B. A., Varanasi, M., Goldenfeld, G., & Steinmetz, N. F. (2026) · Chemical Science · doi:10.1039/d5sc02211h · Cited by 7
Global epidemiology of myocarditis: disparities in age, sex and geography
Klingel, K., Tschöpe, C., Yon, D. K., Mensah, G. A., Weber, B. N., Kontorovich, A., Lee, S., Cooper, L. T., & Ammirati, E. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-026-01276-w · Cited by 9
Genetic ablation of Sarm1 attenuates expression and mislocalization of phosphorylated TDP-43 after mouse repetitive traumatic brain injury
Dogan, E. O., Bouley, J., Zhong, J., Harkins, A. L., Keeler, A. M., Bosco, D. A., Brown, R. H., & Henninger, N. (2023) · Acta Neuropathologica Communications · doi:10.1186/s40478-023-01709-4 · Cited by 7
Self-citation
CRISPR-Based Gene Editing Techniques in Pediatric Neurologic Disorders
Chrzanowski, S. M., & Batra, R. (2022) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2024.01.021 · Cited by 7
On RNA-programmable gene modulation as a versatile set of principles targeting muscular dystrophies
Capelletti, S., Soto, S. C. G., & Gonçalves, M. A. F. V. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.08.016 · Cited by 7
The effects of cannabinoids on the kidney
Didik, S., Palygin, O., Chandy, M., & Staruschenko, A. (2024) · Acta Physiologica · doi:10.1111/apha.14247 · Cited by 7
CDC20 protects the heart from doxorubicin-induced cardiotoxicity by modulating CCDC69 degradation
Feng, Z., Zhang, N., Wang, L., Guan, X., Xie, Y., & Xia, Y. (2025) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-025-00708-8 · Cited by 7
Gene therapy-based strategies for spinal muscular atrophy—an Asia-Pacific perspective
Farrar, M. A., Calotes–Castillo, L. V., de Silva, R., Barclay, P. G., Attwood, L., Cini, J., Ferrie, M. M., & Kariyawasam, D. S. T. (2023) · Molecular and Cellular Pediatrics · doi:10.1186/s40348-023-00171-5 · Cited by 8
Safety concerns surrounding AAV and CRISPR therapies in neuromuscular treatment
Wilton-Clark, H., & Yokota, T. (2023) · Med · doi:10.1016/j.medj.2023.11.008 · Cited by 7
In Vivo CRISPR Activation Screening Reveals Chromosome 1q Genes VPS72, GBA1, and MRPL9 Drive Hepatocellular Carcinoma
Vázquez-Salgado, A. M., Cai, C., Lee, M., Yin, D., Chrystostome, M.-L., Gefre, A. F., He, S., Kieckhaefer, J. E., & Wangensteen, K. J. (2025) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2025.101460 · Cited by 6
A myotropic AAV vector combined with skeletal muscle cis-regulatory elements improve glycogen clearance in mouse models of Pompe disease
Sellier, P., Collaud, F., Benchekroun, Y. K., Jiménez, V., León, X., Danièle, N., Pham, Q. H., Andari, J. E., VandenDriessche, T., Chuah, M., et al. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101464 · Cited by 6
Brogidirsen and Exon 44 Skipping for Duchenne Muscular Dystrophy: Advances and Challenges in RNA-Based Therapy
Tang, A., & Yokota, T. (2025) · Genes · doi:10.3390/genes16070777 · Cited by 6
Antisense oligonucleotide therapy mitigates autosomal dominant progressive hearing loss in a murine model of human DFNA2
Jang, S. H., Roh, J. W., Oh, K. S., Joo, S. Y., Kim, J. A., Kim, S. J., Choi, J. Y., Jung, J., Kim, Y., Bok, J., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.08.044 · Cited by 7
Cell-mediated exon skipping normalizes dystrophin expression and muscle function in a new mouse model of Duchenne Muscular Dystrophy
Galli, F., Bragg, L., Rossi, M., Proietti, D., Perani, L., Bacigaluppi, M., Tonlorenzi, R., Sibanda, T., Caffarini, M., Talapatra, A., et al. (2024) · EMBO Molecular Medicine · doi:10.1038/s44321-024-00031-3 · Cited by 6
Wie sicher ist die Gentherapie?
Horn, S., & Fehse, B. (2024) · Die Innere Medizin · doi:10.1007/s00108-024-01711-5 · Cited by 8
Letter: The risk-benefit balance of CRISPR-Cas screening systems in gene editing and targeted cancer therapy
Yi, Q., Ouyang, X., Zhu, G., & Zhong, J. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05834-z · Cited by 6
Fabry nephropathy: a treatable cause of chronic kidney disease
West, M. L., Geldenhuys, L., & Bichet, D. G. (2024) · Rare Disease and Orphan Drugs Journal · doi:10.20517/rdodj.2023.61 · Cited by 6
The promise of gene therapy in hypertrophic cardiomyopathy: emergence of human experience
Desai, M. Y. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae107 · Cited by 6
Analysis of Hepatic Lentiviral Vector Transduction: Implications for Preclinical Studies and Clinical Gene Therapy Protocols
Hu, P., Hao, Y., Tang, W. H., Diering, G. H., Zou, F., & Kafri, T. (2025) · Viruses · doi:10.3390/v17020276 · Cited by 5
Single-cut gene therapy in a one-step generated rhesus monkey model of Duchenne muscular dystrophy
Bai, R., Guo, W., Zhang, T., Ren, S., Liu, J., Xiao, P., Zhang, J., Sun, W., Yang, J., Ma, Y., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102037 · Cited by 5
Gene therapy in neuronopathic lysosomal storage disorders
Donald, A., Horgan, C., López, M. J. D. C., Jones, S., & Wynn, R. F. (2025) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2025.05.010 · Cited by 6
CRISPR-Cas technologies: Emerging tools from research to clinical application
Hyeon, H., Hwang, S., Luo, Y., Shin, E., Yeom, J., Kim, H., Ryu, M., & Lee, K. (2025) · The Journal of Microbiology · doi:10.71150/jm.2504012 · Cited by 7
CRISPR-Cas editing technologies for viral-mediated gene therapies of human diseases: Mechanisms, progress, and challenges
Kantor, B., Duke, L. C., & Bhide, P. G. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102786 · Cited by 6
Structural basis of liver de-targeting and neuronal tropism of CNS-targeted AAV capsids
Brittain, T. J., Jang, S., Coughlin, G. M., Hoang, J. D., Barcelona, B. H., Giriat, I., Ristic, F., Appling, N., Chossis, C. P., Shay, T. F., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.03.030 · Cited by 7
Safety of Adeno-Associated Viral Vectors in Gene Therapy: Mechanisms of Toxicity, Clinical Risks, and Strategies for Their Minimization
Tsaregorodtseva, T. S., Radyukhina, M. A., Ayupova, A. I., Solovyeva, V. V., Sufianov, A. A., Суфианова, Г. З., & Rizvanov, A. A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27114818 · Cited by 5
Inhibiting EZH2 complements steroid effects in Duchenne muscular dystrophy
Jeon, E. Y., Kwak, Y., Kang, H., Kim, H., Jin, S. Y., Park, S., Kim, R. G., Ko, D., Won, J., Cho, A., et al. (2025) · Science Advances · doi:10.1126/sciadv.adr4443 · Cited by 6
Anti-fibrotic, muscle-promoting antibody-drug conjugates for the improvement and treatment of DMD
Odeh, A., Sela, M., Zaffryar‐Eilot, S., Shemesh, A., Saleh, M. A., Mizrahi, I., Coren, L., Schroeder, A., & Hasson, P. (2025) · iScience · doi:10.1016/j.isci.2025.112335 · Cited by 5
BIN1 gene replacement reverses BIN1-related centronuclear myopathy
Ji, J., Giraud, Q., Diedhiou, N., Lipkow, E., Spiegelhalter, C., & Laporte, J. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.04.036 · Cited by 5
Molecular regulation of myocyte fusion
Wherley, T. J., Thomas, S., Millay, D. P., Saunders, T. E., & Roy, S. (2024) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/bs.ctdb.2024.01.016 · Cited by 8
Adeno‐associated virus vectors for gene therapy—focusing on melanoma
Wang, X., Wei, M., Miao, R., Hao, X., Li, M., Wang, W., & He, Z. (2024) · Interdisciplinary medicine · doi:10.1002/inmd.20240031 · Cited by 6
Treatment of a genetic liver disease in mice through transient prime editor expressionPreprint
Rothgangl, T., Ioannidi, E. I., Weber, Y., Tálas, A., Böck, D., Matsushita, M., Villiger, E. A., Schmidheini, L., Moon, J., Lin, P. J. C., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.01.22.575834 · Cited by 5
Recent developments and industry interest in gene therapy for Duchenne muscular dystrophy
Moriyama, H., & Yokota, T. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2422998 · Cited by 5
The clinical toxicity of advanced therapy medicinal products
Henderson, F. J. H., & Hill, S. L. (2025) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70104 · Cited by 6
mGem: AAV, from almost a virus to an awesome vector—or is it?
Srivastava, A. (2026) · mBio · doi:10.1128/mbio.02957-25 · Cited by 5
CRISPR–Cas3-based editing for targeted deletions in a mouse model of transthyretin amyloidosis
Ishida, S., Sato, Y., Chosa, K., Ezawa, E., Yamauchi, Y., Oyama, M., Kozuka‐Hata, H., Ito, R., Sato, R., Maeki, M., et al. (2026) · Nature Biotechnology · doi:10.1038/s41587-025-02949-6 · Cited by 5
Safety of in vivo gene therapy in children: mechanisms and management of liver injury
Jeyaraj, R., Brown, L. K., Jagadisan, B., Muntoni, F., Baruteau, J., Gupte, G. L., Breuer, J., Gissen, P., Oo, Y. H., & Dhawan, A. K. (2026) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(25)00380-3 · Cited by 4
A compact base editor rescues AATD-associated liver and lung disease in mouse models
Gao, J., Bamidele, N., Pires-Ferreira, D., Zheng, C., Destefano, A., Cheng, H., Tang, Q., Cao, Y., Xie, J., Gao, G., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.08.040 · Cited by 5
Self-citation
Have a Little Heart (or Not): Highly Minimized Skeletal Muscle Regulatory Cassettes with Low or No Activity in the Heart
Himeda, C. L., Jones, T. I., & Jones, P. L. (2024) · Human Gene Therapy · doi:10.1089/hum.2024.041 · Cited by 4
An Imperative for Public Sharing of Adverse Events of Gene Therapy Trials
Bonkowsky, J. L., Rajan, D. S., & Eichler, F. (2025) · JAMA Neurology · doi:10.1001/jamaneurol.2024.4671 · Cited by 4
Pulmonary macrophage transplant therapy in parenchymal lung diseases
O’Callaghan, M., & McCarthy, C. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.101180 · Cited by 4
AAV Kills Dividing Cells by Depleting PARP1 and Other DNA Damage Response ProteinsPreprint
Friese, S., Zai, J., Luzbetak, G., Khanna, N., Gesperger, J., Liu, C.-H., Roos, W. P., Al‐Rahahleh, R. Q., Willardson, M., Yang, F., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.14.682484 · Cited by 4
Heterogeneity, a weak link between constrained AAV dose and long-term efficacy of gene therapy to muscular dystrophy: A critical and prospective review
Lu, Q. L., Zhao, S., & Blaeser, A. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.12.051 · Cited by 3
In vivo gene therapy: A strategy for mutations, degenerations, and tumors
Wang, T., Yu, M., Liu, P., Song, Z., Li, C., Yang, J., & Liu, N. (2025) · Genes & Diseases · doi:10.1016/j.gendis.2025.101808 · Cited by 4
Adeno-associated virus serotype 9 structural heterogeneity and stability characterized by charge detection mass spectrometry
Miller, Z. M., Lin, L. F., Schaffer, D. V., & Williams, E. R. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101608 · Cited by 6
Efficient Scaling up EV‐AAVs Production via Cellular Nanoporation for Familial Hypercholesterolaemia Therapy
Yan, Y., You, Y., Ma, S., Yi, H. J., Chen, G., Ni, J., Chen, C., Ke, W., Li, L., Bai, R., et al. (2025) · Journal of Extracellular Vesicles · doi:10.1002/jev2.70186 · Cited by 3
Corticosteroid treatment in Duchenne muscular dystrophy
Fontaine, S. (2025) · Archives de Pédiatrie · doi:10.1016/s0929-693x(25)00253-2 · Cited by 3
Gene therapy for Parkinson’s disease—Ample room for optimism
Sandoval, I. M., Salvatore, M. F., & Manfredsson, F. P. (2025) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2025.103150 · Cited by 3
Cardiac epigenome in heart development and disease
Laurette, P., & Gilsbach, R. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-025-01223-1 · Cited by 4
Current Trends in Duchenne Muscular Dystrophy Research and Therapy: 3D Cardiac Modelling
Przymuszała, M., Białobrzeska, M., Dulak, J., & Florczyk, U. (2026) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.70180 · Cited by 3
Highly efficient expression of DNA-peptide conjugates in growth-arrested cells
Mohamedshah, Z., Chi, C.-C., Tota, E. M., Komor, A. C., & Devaraj, N. K. (2026) · Nature Communications · doi:10.1038/s41467-025-68167-5 · Cited by 4
Immunogenicity of Gene and Cell Therapies
Hofman, K., Jangied, P., & Balu‐Iyer, S. V. (2026) · BioDrugs · doi:10.1007/s40259-025-00756-8 · Cited by 3
AAV9 Gene Therapy in Type II GM1 Gangliosidosis — A Phase 1–2 Trial
Lewis, C. J., D’Souza, P., Johnston, J. M., Acosta, M. T., Farmer, C., Baker, E. H., Crowell, A., Algarin, Y. M., Ashraf, S., Joseph, L. A., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2510935 · Cited by 3
Self-citation
The application of CRISPR-Cas9 system in brain diseases
Miao, Y., Li, C., Su, Y., Peng, T., Wang, J., Liu, S., Ma, C., Li, L., & Wang, Y. (2026) · Nanomedicine · doi:10.1080/17435889.2026.2629031 · Cited by 3
Self-inactivating AAV-CRISPR at different ages enables sustained amelioration of Huntington’s disease deficits in BAC226Q mice
Dai, Y., Abudujielili, Z., Ding, Y., Huang, W., Yin, J., Ou, L., Hu, J., Zheng, S., & Li, C. (2026) · Science Advances · doi:10.1126/sciadv.aea8052 · Cited by 4
Immune-remodeling mRNAs expressing IRF8 or NIK generate durable antitumor immunity in multiple cancer models
Gupta, A., Das, R., Reed, K., Jeon, T., Nguyen, Q. T. C., Rudra, A., Ge, X., Trongjit, S., Vanrobaeys, Y. S., Langer, R., et al. (2026) · Nature Biotechnology · doi:10.1038/s41587-026-03115-2 · Cited by 6
Death following high-dose AAV9 gene therapy in a patient with advanced SMA-PME
Boespflug‐Tanguy, O., Valent, A., Rambaud, J., Léger, P., Plu, I., Seilhean, D., Frémeaux‐Bacchi, V., Levade, T., Marinello, M., Denard, J., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.05.016 · Cited by 3
Skeletal-muscle-targeted non-viral delivery of full-length DMD mRNA for Duchenne muscular dystrophy
Tian, Y. W., Liu, Y., Tong, Y., Huntoon, K. M., Yang, L., Shi, J., Ma, Y., Dong, S., Jeong, S. D., Estania, A. P., et al. (2026) · Nature Biomedical Engineering · doi:10.1038/s41551-026-01689-5 · Cited by 5
Precision Genetic Therapies: Balancing Risk and Benefit in Patients with Heart Failure
Johnston, J. R., & ADLER, E. D. (2024) · Current Cardiology Reports · doi:10.1007/s11886-024-02096-5 · Cited by 3
AAVolve: Concatenated long-read deep sequencing enables whole capsid tracking during shuffled AAV library selection
Scott, S., Westhaus, A., Nazareth, D., Cabanes‐Creus, M., Navarro, R. G., Chandra, D., Zhu, E., Venkateswaran, A., Alexander, I. E., Bauer, D. C., et al. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101351 · Cited by 4
X-linked myotubular myopathy: an untreated treatable disease
Martín, C., & Servais, L. (2025) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2025.2473430 · Cited by 3
AAV Immunotoxicity: Implications in Anti-HBV Gene Therapy
Jacobs, R., Dogbey, D. M., Mnyandu, N., Neves, K., Barth, S., Arbuthnot, P. B., & Maepa, M. B. (2023) · Microorganisms · doi:10.3390/microorganisms11122985 · Cited by 3
Advances in microbubble-assisted ultrasound-guided gene therapy: Mechanisms and applications
Tie, Z., Zhang, S., Qu, Y., Wang, M., Liu, R., Sun, D., & Dai, Z. (2024) · Science China Materials · doi:10.1007/s40843-024-2993-4 · Cited by 4
Clinician Perspectives of Gene Therapy as a Treatment Option for Duchenne Muscular Dystrophy
Cope, H., Fischer, R., Heslop, E., McNiff, M. M., Johnson, A., Camino, E., Denger, B., Armstrong, N., Thakrar, S., Bateman-House, A., et al. (2024) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-240033 · Cited by 3
Identification of a novel neutralization epitope in rhesus AAVs
Dagotto, G., Fisher, J. L., Li, D., Li, Z., Jenni, S., Li, Z., Tartaglia, L. J., Abbink, P., & Barouch, D. H. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101350 · Cited by 3
Challenges in Cardiomyopathy Gene Therapy Clinical Trial Design
Satish, T., Hong, K. N., Kaski, J. P., & Greenberg, B. H. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2024.08.024 · Cited by 3
Effective Reduction of Transgene‐Specific Immune Response With rAAV Vectors Co‐Expressing miRNA ‐ UL112 ‐5p or ERAP1 shRNA
Xiao-ping, H., Wang, X., Sun, Y., Xie, X., Xiao, L., Xu, Y., Yan, Q., Xu, X., Li, L., Xu, W., et al. (2025) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70308 · Cited by 3
The latest developments in synthetic approaches to Duchenne muscular dystrophy
Johnson, L. M., Pulskamp, T. G., & Berlau, D. J. (2025) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2025.2462281 · Cited by 4
Crossing the Threshold of Therapeutic Hope for Patients With PKP2 Arrhythmogenic Cardiomyopathy
Mundisugih, J., & Kizana, E. (2024) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.124.004572 · Cited by 3
CRISPR screen for rAAV production implicates genes associated with infectionPreprint
O'Driscoll, E., Arora, S., Lang, J. F., Davidson, B. L., & Shalem, O. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.09.17.613356 · Cited by 3
AAV9 Gene Therapy in GM1 Gangliosidosis Type II: A Phase 1/2 TrialPreprint
Lewis, C. J., D’Souza, P., Johnston, J. M., Acosta, M. T., Farmer, C., Baker, E. H., Crowell, A., Algarin, Y. M., Rahman, S., Joseph, L. A., et al. (2025) · medRxiv · doi:10.1101/2025.07.28.25332074 · Cited by 3
Self-citation
CRISPR screen reveals modifiers of rAAV production including known rAAV infection genes playing an unexpected role in vector production
O'Driscoll, E., Arora, S., Lang, J. F., Davidson, B. L., & Shalem, O. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101408 · Cited by 5
Gene therapy restores auditory function and rescues damaged inner hair cells in an aged Vglut3 knockout mouse model
Zhao, X., Xu, H., Lian, C., Hu, S., Zhao, Y., Wang, J., Zhai, R., Yang, M., Zhang, Y., Lu, W., et al. (2025) · Gene Therapy · doi:10.1038/s41434-025-00558-1 · Cited by 2
Gene Replacement Therapy in Patients With Cardiac Disease: Challenges in Trial Design and Management of Adverse Events
Maurizi, N., Hong, K. N., Silver, E., Patel, U., & ADLER, E. D. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.08.340 · Cited by 2

Authors: Lek, A., Wong, B., Keeler, A., Blackwood, M., Ma, K., Huang, S., Sylvia, K., Batista, A. R., Artinian, R., Kokoski, D., Parajuli, S., Putra, J., Carreon, C. K., Lidov, H., Woodman, K., Pajusalu, S., Spinazzola, J. M., Gallagher, T., LaRovere, J., Balderson, D., Black, L., Sutton, K., Horgan, R., Lek, M., & Flotte, T.
Affiliations: Yale University (US)
University of Massachusetts Chan Medical School (US)
Boston Children's Hospital (US)
Tartu University Hospital (EE)
Wake Technical Community College (US)
Charles River Laboratories (United States) (US)
Cure Rare Disease, Woodbridge, CT, USA.
ORCID: Lek, Angela
Wong, Brenda
Keeler, Allison
Blackwood, Meghan
Ma, Kaiyue
Huang, Shushu
Batista, A. Rita
Parajuli, Shestruma
Putra, Juan
Carreon, C. Katte
Lidov, Hart
Woodman, Keryn
Pajusalu, Sander
Spinazzola, Janelle M.
Gallagher, Thomas
LaRovere, Joan
Lek, Monkol
Flotte, Terence
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2023-09-28
Volume: 389
Issue: 13
Pages: 1203-1210
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa2307798
PMC: PMC11288170
OpenAlex: W4387077861
Cited by: 319
References: 26
Citations by year: 2026: 80 · 2025: 125 · 2024: 97 · 2023: 17
FWCI: 52.96
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Heart, Lung, and Blood Institute (P01HL158506)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords: Duchenne muscular dystrophy, gene therapy toxicity, acute respiratory distress syndrome, cardiac arrest, diffuse alveolar damage, innate immune response, autopsy
MeSH terms: Adult, Antibodies, Humans, Immunity, Innate, Respiratory Distress Syndrome, Genetic Therapy, Dystrophin, Fatal Outcome, Transgenes, Muscular Dystrophy, Duchenne

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Death after High-Dose rAAV9 Gene Therapy in a Patient with Duchenne’s Muscular Dystrophy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks